In an SEC filing, Erasca said its realignment is meant to keep RAS-targeting programs moving through development and toward possible commercialization, with Chief Operating Officer Nicholas (Nik) Chetwyn, Ph.D., scheduled to leave Nov. 2.
Erasca said the redistribution of COO responsibilities among its leadership team would streamline the company’s reporting structure.



